Objective To investigate the clinical effect of atorvastatin combined with psychological intervention in elderly patients with coronary heart disease. Methods According to the different treatment and nursing intervention mode will be January 2015 to April 2017 year in April in our hospital 120 patients with coronary heart disease groups: control group with routine nursing intervention mode enalapril treatment, the observation group used atorvastatin+psychological nursing intervention therapy; the two groups of patients with clinical symptoms, improve psychological status and the incidence of adverse reactions were recorded, and the related data for comparative analysis. Results Atorvastatin statin+psychological nursing mode (observation group) intervention in the treatment of senile coronary heart disease clinical effect is better than that of enalapril+routine nursing (control group) treatment intervention, patients with clinical symptoms improved better than the control group, the mental state improved better than the control group, the incidence rate of adverse reaction was lower than the control group, the difference was statistically significant (P< 0.05). Conclusion The effect of atorvastatin + psychological nursing intervention in elderly patients with coronary heart disease is remarkable. It can effectively improve the clinical symptoms and psychological status of patients, and have less adverse reactions. It is worthy of clinical application.

Objective To observe the effect of doxofylline and budesonide combined with psychological intervention on the treatment of the patients with bronchial asthma, and evaluate its clinical effect. Methods From March 2014 to February 2017 in Guangfu hospital, 148 cases with bronchial asthma were divided into the control group and the experimental group by randomized double blind digit table with 74 cases in each group. The control group were given doxofylline and budesonide combined with routine nursing intervention, at this basis, the experimental group were receive psychological intervention. The clinical effect in the two groups were compared. Results The total effective rate was 95.95% (71/74) in the experimental group while 79.73%(59/74) in the control group, the difference was statistically significant between the two groups(P<0.05); Compared with before treatment, FEV1, FVC, VC and other indicators after treatment were significantly improved, and the experimental group improved significantly better than those in the control group (P<0.05). Conclusion Doxofylline and budesonide combined with psychological intervention on the treatment of the patients with bronchial asthma has obvious curative effect, which can effectively improve the lung function, accelerate the symptoms disappeared time, and worthy of clinical application.

Objective:To investigate the efficacy of osettinib in the treatment of first-line tyrosine kinase inhibitor-resistant advanced lung adenocarcinoma and its effects on carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) levels.Methods:Seventy-two patients with first-line tyrosine kinase inhibitor-resistant advanced lung adenocarcinoma (T790M test negative or rejected) who received treatment in Jinhua Guangfu Cancer Hospital from June 2017 to June 2019 were included in this study. They were randomly assigned to undergo either conventional pemetrexed plus cisplatin (control group, n = 36) or osimertinib mesylate (observation group, n = 36) for 4 successive weeks. Before and after 4 weeks of treatment, serum CEA and VEGF levels were measured. Curative effects were evaluated. Adverse reactions and 6-month, 1-year and 2-year survival rate were recorded. Results:Effective rate and disease-control rate in the observation group were 80.6% (29/36) and 94.4% (34/36) respectively, which were significantly higher than 58.3% (21/36) and 75.0% (27/ 36) in the control group ( χ2 = 4.193, 5.261, both P < 0.05). Before treatment, there were no significant differences in serum CEA and VEGF levels between the two groups (both P > 0.05). Compared with before treatment, serum CEA and VEGF levels were significantly increased after treatment (both P < 0.05). After treatment, serum CEA and VEGF levels in the observation group were (5.36 ± 0.33) U/mL and (121.56 ± 11.57) ng/L respectively, which were significantly lower than those in the control group [(8.25 ± 0.54) U/mL, (163.68 ± 14.59) ng/L, t = 27.399, 13.572, both P < 0.001]. The incidence of adverse reactions in the observation group was significantly lower than that in the control group [19.4% (7/36) vs. 44.4% (16/36), χ2 = 5.173, P = 0.011]. 6-month, 1-year and 2-year survival rate were 94.29%, 77.14% and 60.00% respectively, in the observation group and 91.43%, 54.29% and 34.29% respectively in the control group. There was no significant difference in 6-month overall survival rate between the two groups ( χ2 = 0.352, P = 0.251). 1-year and 2-year survival rate in the observation group were significantly higher than those in the control group ( χ2 = 4.058, P = 0.044; χ2 = 4.644, P = 0.031). Conclusion:Ositinib is effective in the targeted treatment of first-line tyrosine kinase inhibitor-resistant advanced lung adenocarcinoma. It can effectively decrease serum CEA and VEGF levels and prolong the survival of patients, thereby exhibiting a clinical application value.